Baird upgraded Achillion Pharmaceuticals (Nasdaq: ACHN) from Neutral to Outperform and moves its price target from $14 to $12 ahead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE